The 2025 proposed CMS rule has some exciting news for #digitaltherapeutic devices. The proposed rule represents a significant advancement in expanding access to behavioral health services and DANA Brain Vital stands ready to play a pivotal role in this new era by providing objective outcome measurements on the efficacy of therapeutic interventions on cognitive function. Our advanced capabilities ensure that digital therapeutic companies can confidently demonstrate the impact of their products, thus meeting CMS requirements and optimizing patient care. DANA seamlessly integrates into existing application platforms, eliminating the need for it to be used as a separate application. This streamlined integration simplifies the process for digital therapeutic companies and enhances the overall user experience. Moreover, DANA offers additional revenue opportunities for digital therapeutic clients by enabling them to leverage existing billing codes for therapeutic monitoring. https://lnkd.in/g2WT-22e
Abby Thompson Exciting developments with the 2025 CMS rule! How do you see DANA Brain Vital transforming the landscape of behavioral health services?
It's great to see advancements in expanding access to behavioral health services through the proposed CMS rule. Objective outcome measurements will undoubtedly play a crucial role in demonstrating the efficacy of therapeutic interventions. How do you envision digital therapeutic companies utilizing tools like DANA Brain Vital to meet CMS requirements and improve patient care?